The negotiated Medicare price for Ozempic will fall to $274 a month on January 1, down from a list price of $959, one of the steepest reductions in the second round of the federal drug-pricing program. The cut applies across Medicare’s Part D drug plans rather than to a single insurer, and it lands on one of the most-prescribed and most-expensive medications the program covers. For the millions of older adults managing type 2 diabetes, and for the government that pays most of the tab, the change reworks a line item that has strained budgets on both sides of the counter.
How Medicare Cut Ozempic From $959 to $274
The reduction flows from the price-negotiation authority Congress handed Medicare in 2022, which lets the program bargain directly over its highest-spending drugs instead of accepting the manufacturer’s list price. Ozempic’s maker, Novo Nordisk, agreed to the new figure in the program’s second cycle, a batch of 15 drugs whose negotiated prices were published by the government and set to begin next year. The gap between $959 and $274 amounts to a discount of roughly 71%, among the largest in the group.
The scale extends well beyond one medication. Across all 15 drugs, the negotiated prices take effect January 1, 2027, with reductions ranging from 38% to 85% and a projected cut of about 44% in what Medicare spends on those treatments. Independent analysts have estimated the round could save the program and taxpayers on the order of $12 billion a year measured against prior spending, a figure that reflects how concentrated Medicare’s drug budget has become in a handful of blockbuster products.
The negotiation itself is not a simple discount coupon. Manufacturers and Medicare exchange offers over months, with the government weighing a drug’s clinical benefit, the existence of therapeutic alternatives, and its total cost to the program, and the published figure becomes the maximum fair price that plans may not exceed. Reaching $274 required Novo Nordisk to accept a number far below the list price it had long defended, a concession that shows how much leverage the program gains the moment a drug is selected for negotiation rather than left off the list.
Free retirement updates: Social Security and Medicare change every year, and nobody sends a memo. The free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
What Beneficiaries Actually Pay at the Pharmacy Counter
The $274 is the price Medicare and its drug plans pay, not necessarily the amount a beneficiary hands over. A person’s share still depends on the plan’s deductible, its coinsurance tier for the drug, and where the person stands against the program’s annual out-of-pocket limit on Part D spending, which caps a beneficiary’s yearly drug outlay at $2,100 in 2026. For someone who already hits that ceiling, a lower negotiated price changes what the system spends more than what the household pays in a heavy year.
Coverage rules narrow the benefit further. Medicare covers Ozempic for type 2 diabetes, not for weight loss, so the discount reaches diabetic beneficiaries rather than the broader population that seeks the drug for other reasons. Wegovy, the higher-dose version of the same semaglutide molecule marketed for weight management, was negotiated separately and lands at a higher monthly figure, a distinction that determines exactly who sees the savings and who does not.
The timing is fixed to the plan year. Because the negotiated price starts on January 1, 2027, beneficiaries will see any downstream effect reflected in their 2027 Part D coverage rather than in this year’s plan, and the practical impact will vary plan by plan as insurers rebuild their formularies and cost-sharing around the new number.
Why a Single Drug’s Price Moves the Whole Program
Semaglutide has become one of Medicare’s largest single spending lines as demand for GLP-1 drugs has surged, which is precisely why it was named in the second negotiation round rather than left for a later cycle. When one product accounts for billions in annual outlays, shaving its price does more for the program’s finances than trimming dozens of smaller drugs, and it reshapes the incentives insurers weigh when they design coverage.
The negotiation program has also cleared its early legal and political tests, and the government has continued to add drugs each cycle, widening the list into new therapeutic areas. That trajectory matters for retirees because it signals a durable shift in how Medicare sets prices on its costliest medications rather than a one-time headline, with more widely used drugs likely to face the same treatment in future rounds.
The change also arrives against a backdrop of demand that Medicare cannot easily switch off. Prescriptions for semaglutide and related drugs have climbed steeply among older adults managing diabetes, so even a sharply lower unit price can leave total program spending high simply because so many beneficiaries fill the prescription each month. That dynamic is part of why officials targeted the drug in this cycle rather than waiting, and why the savings estimate is measured against what Medicare would otherwise have paid at the old price rather than against a shrinking pool of patients.
The discount is locked in for 2027, but what a beneficiary feels at the register depends on plan design and the out-of-pocket cap already in place, not on the negotiated figure alone. The larger effect may register on Medicare’s balance sheet and in the premiums and formulary choices that follow, which is where a $685-a-month price cut on a single drug ultimately circles back to the people who fund and rely on the program.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
